Priapus Toxin™: A Specific Method of Using Botulinum Toxin for Erectile Dysfunction
FAIRHOPE, Ala., Sept. 11, 2023 /PRNewswire/ -- Dr. Charles E. Runels Jr., M.D., the President of Cellular Medicine Association, Inc. ("CMA"), has now applied for registration of the trademark PRIAPUS TOXIN™ for "medical services, namely, injecting the corpus cavernosi of the penis with therapeutic neurotoxins to improve penile health and to enhance erectile function or penis size."
- Allergan Inc., the manufacturer of the BOTOX®-branded neurotoxin, has agreed not to challenge Dr. Runels' and CMA's use or registration of the mark PRIAPUS TOXIN™.
- While Dr. Runels had previously applied to register the trademark BOCOX and asked for Allergan's consent, Allergan objected to the use and registration of the trademark BOCOX.
- For evaluation and for possible treatment, men should find the nearest provider licensed by the CMA to provide the Periapsis Toxin™ —on the directory at PriapusShot.com/members/directory .
- Physicians of the CMA conduct and consult regarding research in the areas of esthetics, erectile dysfunction, urinary incontinence, orgasmic dysfunction in women, lichen sclerosus, & other treatments for many other problems—using cellular therapies, especially blood-derived growth factors, including platelet-rich plasma.